Literature DB >> 28126964

Prostacyclin-analog therapy in sickle cell pulmonary hypertension.

Nargues A Weir1, Rehan Saiyed2, Shoaib Alam1, Anna Conrey2, Himanshu D Desai3, M Patricia George4, Jennifer H Keeley4, Elizabeth S Klings5, Alem Mehari6, James G Taylor2, Caterina P Minniti7, Gregory J Kato8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28126964      PMCID： PMC5477616          DOI： 10.3324/haematol.2015.131227

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Pulmonary hypertension in patients with sickle cell disease: not so frequent but so different.

Authors:  G Simonneau; F Parent
Journal:  Eur Respir J       Date:  2012-01       Impact factor: 16.671

Review 2.  Dose-dependent reduction in pulmonary vascular resistance with epoprostenol in pulmonary arterial hypertension.

Authors:  Satoshi Homma
Journal:  Circ J       Date:  2010-09-11       Impact factor: 2.993

3.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

4.  Is resistance futile?: Hemodynamics in sickle cell disease.

Authors:  Kerri Akaya Smith; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

5.  Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.

Authors:  S C Apostolopoulou; A Manginas; D V Cokkinos; S Rammos
Journal:  Heart       Date:  2005-03-10       Impact factor: 5.994

Review 6.  Diagnosis and treatment of pulmonary artery hypertension.

Authors:  R J Barst
Journal:  Curr Opin Pediatr       Date:  1996-10       Impact factor: 2.856

7.  Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.

Authors:  Raymond L Benza; Robyn J Barst; Nazzareno Galie; Adaani Frost; Reda E Girgis; Kristin B Highland; Charlie Strange; Carol M Black; David B Badesch; Lewis Rubin; Thomas R Fleming; Robert Naeije
Journal:  Chest       Date:  2008-07-14       Impact factor: 9.410

8.  Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.

Authors:  Christopher F Barnett; Eric J Bonura; Steven D Nathan; Shahzad Ahmad; Oksana A Shlobin; Kwabena Osei; Ari L Zaiman; Paul M Hassoun; David R Moller; Scott D Barnett; Reda E Girgis
Journal:  Chest       Date:  2008-12-31       Impact factor: 9.410

9.  Causes of death in sickle cell disease: an autopsy study.

Authors:  Elizabeth A Manci; Donald E Culberson; Yih-Ming Yang; Todd M Gardner; Randall Powell; Johnson Haynes; Arvind K Shah; Vipul N Mankad
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

10.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.

Authors:  Oswaldo Castro; Mohammed Hoque; Bernice D Brown
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113
View more
  8 in total

Review 1.  Cardiovascular complications in patients with sickle cell disease.

Authors:  Mark T Gladwin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Sickle related events following cardiac catheterisation: risk implication for other invasive procedures.

Authors:  Rosario Di Maggio; Anna Conrey; Tiffani N Taylor; Robert J Lederman; Toby Rogers; Jim Nichols; Shenikqua Bouges; Caterina P Minniti; Gregory J Kato; Arun S Shet; Matthew M Hsieh
Journal:  Br J Haematol       Date:  2018-10-23       Impact factor: 6.998

3.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.

Authors:  Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  How I treat the older adult with sickle cell disease.

Authors:  Swee Lay Thein; Jo Howard
Journal:  Blood       Date:  2018-09-11       Impact factor: 22.113

Review 5.  What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?

Authors:  Shaina M Willen; Mark T Gladwin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.

Authors:  A Parker Ruhl; S Christy Sadreameli; Julian L Allen; Debra P Bennett; Andrew D Campbell; Thomas D Coates; Dapa A Diallo; Joshua J Field; Elizabeth K Fiorino; Mark T Gladwin; Jeffrey A Glassberg; Victor R Gordeuk; Leroy M Graham; Anne Greenough; Jo Howard; Gregory J Kato; Jennifer Knight-Madden; Benjamin T Kopp; Anastassios C Koumbourlis; Sophie M Lanzkron; Robert I Liem; Roberto F Machado; Alem Mehari; Claudia R Morris; Folasade O Ogunlesi; Carol L Rosen; Kim Smith-Whitley; Danna Tauber; Nancy Terry; Swee Lay Thein; Elliott Vichinsky; Nargues A Weir; Robyn T Cohen; Elizabeth S Klings
Journal:  Ann Am Thorac Soc       Date:  2019-09

Review 7.  Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.

Authors:  Mazen Al-Qadi; Barbara LeVarge; H James Ford
Journal:  Front Med (Lausanne)       Date:  2021-03-25

Review 8.  Sickle cell disease: a review for the internist.

Authors:  Valeria Maria Pinto; Manuela Balocco; Sabrina Quintino; Gian Luca Forni
Journal:  Intern Emerg Med       Date:  2019-08-05       Impact factor: 5.472
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.